Figure 1.
Study flow diagram.
Table 1.
Characteristics of studies of ANA, SMA and SLA/LP.
Figure 2.
A cumulative bar plot of methodological quality items across ANA, SMA and anti-SLA/LP studies.
Figure 3.
SROC curves for ANA, SMA and anti-SLA/LP.
Each solid circle represents each study in the meta-analysis. The size of each study is indicated by the size of the solid circle. SROC = summary receiver operative curve, ANA = antinuclear antibodies, SMA = smooth muscle antibodies, anti-SLA/LP = antibodies to a soluble liver antigen/liver pancreas, AUC = area under the curve, SE = standard error, Q* = Cochran Q.
Table 2.
Summary values of ANA, SMA and anti-SLA/LP for all studies and different subgroups.
Figure 4.
Forest plots of estimates of sensitivity and specificity for different subgroups.
Each solid circle indicates the point estimate of sensitivity and specificity from each study in the meta-analysis. Error bars indicate 95% confidence intervals. There are different colors presenting subgroups. As for different race, blue, orange and pink represent Europe, and red, yellow and green represent Asia in three groups (ANA, SMA and anti-SLA/LP), respectively. Meanwhile, olive is immunoblot and purple is non-immunoblot assay for different assays of detecting anti-SLA/LP. ANA = antinuclear antibodies, SMA = smooth muscle antibodies, anti-SLA/LP = antibodies to a soluble liver antigen/liver pancreas.
Figure 5.
Funnel plots for the assessment of potential publication bias in ANA, SMA and anti-SLA/LP.
The funnel graph plots the log of the DOR against the standard error of the log of the DOR (an indicator of sample size). Each open circle represents each study in the meta-analysis. The line in the center indicates the summary DOR. ANA = antinuclear antibodies, SMA = smooth muscle antibodies, anti-SLA/LP = antibodies to a soluble liver antigen/liver pancreas. DOR = diagnostic odds ratio.